NCT04794738

Brief Summary

The primary objective is to evaluate the analgesic efficacy of IV SHR8554 compared with placebo and morphine in patients with acute postoperative pain following orthopedic surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
192

participants targeted

Target at P75+ for phase_2 pain

Timeline
Completed

Started Apr 2021

Shorter than P25 for phase_2 pain

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 12, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

April 18, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2021

Completed
Last Updated

August 12, 2021

Status Verified

March 1, 2021

Enrollment Period

7 months

First QC Date

March 9, 2021

Last Update Submit

August 5, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • the Sum of Pain Intensity Differences in Pain Score Over 48 Hours in the rest state

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 48 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (48 hours) to yield values on the 0-10 NPRS.

    48-hours

Secondary Outcomes (6)

  • the Sum of Pain Intensity Differences in Pain Score Over 6、12、48 、12-24、24-48 Hours under static condition

    48-hours

  • the Sum of Pain Intensity Differences in Pain Score Over 6、12、24、48 、12-24、24-48 Hours under moving condition

    48-hours

  • Time of first use of remedial analgesic medication

    48-hours

  • Cumulative use of remedial analgesics from 0h to 48h

    48-hours

  • Participant ' satisfaction score for analgesia treatment

    48-hours

  • +1 more secondary outcomes

Study Arms (4)

Treatment group A

EXPERIMENTAL
Drug: SHR8554

Treatment group B

EXPERIMENTAL
Drug: SHR8554

Treatment group C

PLACEBO COMPARATOR
Drug: Saline Solution

Treatment group D

ACTIVE COMPARATOR
Drug: Morphine

Interventions

SHR8554 Injection; high dose

Treatment group A

Saline Solution

Treatment group C

Morphine

Treatment group D

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able and willing to provide a written informed consent
  • Subjects requiring elective general anesthesia orthopedic surgery
  • Conform to the ASA Physical Status Classification

You may not qualify if:

  • Subjects with a history of difficult airway
  • Subjects with a history of reflux esophagitis
  • Subjects with a history of mental illness
  • Subjects with poor blood pressure control
  • Transcutaneous oxygen saturation (SpO2) \<90%
  • Random blood glucose ≥11.1mmol/L
  • Subjects with abnormal liver function
  • allergies to opioids and other medications that may be used during the trial
  • Pregnant or nursing women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Jiaotong University School of Medicine,Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

RECRUITING

MeSH Terms

Conditions

Pain

Interventions

Saline SolutionMorphine

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel Assignment
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 9, 2021

First Posted

March 12, 2021

Study Start

April 18, 2021

Primary Completion

October 30, 2021

Study Completion

October 30, 2021

Last Updated

August 12, 2021

Record last verified: 2021-03

Locations